BOLD (Boundless Bio) 6-Month Price Index: 2.58 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOLD Boundless Bio Inc BOLD
14 GF Score
Price $3.00
! 3 Warning Signs
View Full Analysis

What is Boundless Bio 6-Month Price Index?

Boundless Bio BOLD +3.45% 14 6-Month Price Index is 2.58 as of Aug. 23, 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-23), Boundless Bio's 6-Month Price Index is 2.58.

Boundless Bio  (NAS:BOLD) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Boundless Bio 6-Month Price Index Related Terms

BOLD vs XLO, CNTX, INKT: 6-Month Price Index Comparison

For the Biotechnology subindustry, Boundless Bio's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BOLD
14GF Score
Boundless Bio Inc BOLD
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boundless Bio  (NAS:BOLD) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 2.58 mean?
Boundless Bio (BOLD) has a 6-Month Price Index of 2.58 as of Aug. 23, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Boundless Bio and its competitors.
Is Boundless Bio's 6-Month Price Index too high?
Boundless Bio's current 6-Month Price Index is 2.58. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's 6-Month Price Index compare to XLO and CNTX?
Boundless Bio's 6-Month Price Index of 2.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Boundless Bio and its competitors. Boundless Bio's current 6-Month Price Index is 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current 6-Month Price Index of 2.58. The current 6-Month Price Index is 2.58. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Boundless Bio (BOLD), the current 6-Month Price Index is 2.58 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Boundless Bio Business Description

Address 10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score

Get the complete analysis for BOLD

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price